Mitochondrial Donation: The Science Behind Three-Person Babies And The End Of Inherited Disease

Every cell in your body contains two separate sets of genetic instructions. The first — nearly 20,000 genes encoding the proteins that build and run your body — sits in the cell nucleus, inherited from both parents in equal measure. The second is smaller, older, and far less discussed: 37 genes carried in the mitochondria, the energy-producing structures that power every cell, inherited exclusively from your mother.

For the vast majority of people, mitochondrial DNA is invisible — a functional background system that simply works. But for approximately one in 5,000 people, it does not work. Mutations in mitochondrial DNA cause a group of severe, progressive, and often fatal conditions — mitochondrial diseases — that rob cells of the energy they need to function. The brain, heart, muscles, and liver are most severely affected, because these organs have the highest energy demands. There is no cure. Until recently, there was no way to prevent transmission from mother to child.

That has changed. Mitochondrial donation treatment — a form of IVF that replaces faulty mitochondrial DNA with healthy mitochondria from a donor — has now produced healthy babies free from hereditary mitochondrial disease. The United Kingdom became the first country to legalise the technique in 2015. The first British baby born using the technique arrived in 2023. Clinics in other countries, including Australia, are now following. This is not a distant promise. It is a medical reality — and one with implications that extend well beyond the families it most immediately helps.

What Are Mitochondria and Why Do They Matter?

Mitochondria are membrane-enclosed structures found in almost every cell of the body. Their primary function is producing ATP — adenosine triphosphate — the molecule that cells use as their primary energy currency. Every muscular contraction, every nerve impulse, every biochemical reaction that requires energy draws on ATP produced by mitochondria. A cell without functioning mitochondria is a cell that cannot maintain itself.

Mitochondria are unusual among cellular structures in having their own DNA — a small circular genome of approximately 16,500 base pairs, encoding 37 genes. This is a relic of the evolutionary origin of mitochondria: they were once free-living bacteria that were incorporated into ancient eukaryotic cells in a symbiotic relationship that proved so successful it became permanent. Over billions of years, most of the original bacterial genes were transferred to the nuclear genome, but 37 were retained in the mitochondria themselves.

Mitochondrial DNA is inherited exclusively through the maternal line. Unlike nuclear DNA, which undergoes recombination — the shuffling of genetic material between chromosomes that occurs during the formation of eggs and sperm — mitochondrial DNA is transmitted essentially unchanged from mother to child. A woman with a mitochondrial DNA mutation will pass it to all of her children. Her daughters will in turn pass it to their children. There is no natural mechanism for clearing a mitochondrial mutation from a maternal lineage once it is present.

This maternal inheritance pattern, combined with the severity of mitochondrial diseases, is what makes mitochondrial donation treatment both scientifically necessary and ethically significant.

What Is Mitochondrial Donation Treatment?

Mitochondrial donation treatment is an IVF technique that produces an embryo containing nuclear DNA from both biological parents combined with mitochondrial DNA from a healthy female donor. The resulting child inherits the vast majority of their genetic identity from their two parents — all of the roughly 20,000 nuclear genes that determine almost every heritable trait — while carrying donor mitochondrial DNA in place of the mother’s faulty version.

Because mitochondrial DNA encodes only 37 genes, all involved in energy production, and because these genes have no known influence on physical appearance, personality, intelligence, or any other trait associated with individual identity, the donor’s contribution is sometimes described as providing a “battery pack” rather than a genetic identity. The child will have three genetic contributors but two biological parents in any meaningful sense.

Two main techniques have been developed. Maternal spindle transfer removes the spindle — the structure around which chromosomes organise during cell division — from the mother’s egg and transfers it into a donor egg from which the donor’s nucleus has been removed. The reconstructed egg, containing the mother’s nuclear genetic material and the donor’s mitochondria, is then fertilised by the father’s sperm.

Pronuclear transfer takes a different approach: both the mother’s egg and the donor egg are fertilised by the father’s sperm, creating two embryos. The pronuclei — the nuclear structures present before full fertilisation is complete — are then transferred from the affected embryo to the donor embryo from which the donor’s pronuclei have been removed. This technique involves the creation and subsequent destruction of an embryo, which raises additional ethical considerations and is not preferred in clinical practice where maternal spindle transfer is available.

The Families It Helps

Mitochondrial diseases affect approximately one in 5,000 people, but the burden is concentrated. Some mutations are severe and ubiquitous — affecting every cell — while others are milder or present in only a fraction of cells (a situation called heteroplasmy). The most severe mitochondrial conditions include Leigh syndrome, which causes progressive neurological deterioration typically beginning in infancy and leading to death within a few years; MELAS syndrome, characterised by mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes; and Pearson syndrome, a multisystem disorder affecting the bone marrow and pancreas.

For families affected by severe mitochondrial disease, the existing options before mitochondrial donation treatment were limited and deeply painful. Prenatal diagnosis could identify affected foetuses, but the decision to terminate a pregnancy on these grounds is one that many families find unacceptable. Preimplantation genetic testing — screening embryos created through IVF for mitochondrial mutations before implantation — is possible for some mutations but unreliable for others, particularly when heteroplasmy makes it impossible to predict whether a low level of mutant mitochondria in a tested embryo will cause disease. Using donor eggs eliminates the risk but means the child shares no nuclear genetic material with the mother.

Mitochondrial donation treatment offers something none of these alternatives provides: a child who is genetically the mother’s own in every meaningful sense, free from the mitochondrial mutation that has in some cases affected multiple generations of the family.

The First Babies and the Evidence So Far

The first children born using mitochondrial donation treatment are now several years old. The Newcastle Fertility Centre, which became the first licensed clinic to offer the treatment in the United Kingdom, has reported that the technique has successfully prevented mitochondrial disease transmission in treated cases, with no serious adverse outcomes in either mothers or children reported to date.

Outside the UK, several children born using the technique in other jurisdictions — including cases in Mexico and Ukraine, where the technique was used in research contexts before formal licencing — have been followed up and found to be healthy. The longest-followed cases are now approaching a decade, providing initial reassurance about safety but not yet the multigenerational data that would constitute a full safety assessment.

One concern that has been raised is the possibility of mitochondrial reversal — a phenomenon in which residual mutant mitochondria carried over during the nuclear transfer procedure gradually outcompete the donor mitochondria, partially or fully restoring the original mitochondrial mutation in the child. This has been observed in some animal studies and in at least one human case. The risk is considered low but not negligible, and it is one reason why follow-up of children born using the technique is being conducted with particular care.

The Ethical Debate

Mitochondrial donation treatment has generated significant ethical debate since it was first proposed, and that debate has not been fully resolved despite the technique now being in clinical use.

The most fundamental objection concerns germline modification. Unlike somatic gene therapies — treatments that modify the DNA of specific tissues in a living patient — mitochondrial donation treatment modifies the germline: the genetic material that will be passed to all future generations descended from the treated individual. The child’s daughters will inherit the donor mitochondria and pass them to their own children. This represents a permanent change to a human lineage, made on behalf of people not yet born who cannot consent.

Proponents of the technique argue that this germline modification is qualitatively different from the germline modification feared in discussions of nuclear gene editing. The mitochondrial genome is small, its functions are limited to energy production, and the donor contribution has no known influence on the traits that constitute individual identity. The modification eliminates suffering rather than enhancing traits. The moral calculus, in this view, is clear.

Critics argue that the precedent of heritable genetic modification — however limited in scope — is concerning regardless of the specific genes involved. Once society accepts that some heritable modifications are permissible, the boundary against others becomes harder to maintain. This is the slippery slope argument, and it has been taken seriously enough that the regulatory frameworks in countries licencing the technique have been designed with exceptional care to limit its application strictly to the prevention of serious mitochondrial disease.

Questions about the identity of the donor — whether children born using the technique have a right to know the identity of their mitochondrial donor, and what relationship if any they might seek — are also being addressed through emerging regulatory guidance. The UK has moved toward a system in which children can access information about their mitochondrial donor upon reaching adulthood, treating the donor’s contribution with a seriousness proportionate to its novelty.

For a broader look at the ethical landscape of genetic modification technologies, see our article on designer babies: the reality and myths of genetic optimisation in embryos. For an exploration of how CRISPR and other gene editing tools are being applied to human medicine, see our article on gene editing in 2026.

The Global Regulatory Landscape

The United Kingdom remains the only country to have established a formal regulatory framework for clinical mitochondrial donation treatment and licenced clinics to offer it to patients. The Human Fertilisation and Embryology Authority oversees the licensing process, requiring each case to be individually reviewed and approved before treatment can proceed.

Australia passed legislation in 2022 permitting a clinical trial of mitochondrial donation treatment, with the first Australian clinic licenced to offer the treatment in 2023. Several other countries are in various stages of regulatory consideration. The United States, where mitochondrial donation research has been conducted but clinical use remains prohibited under a Congressional rider attached to FDA appropriations, faces ongoing policy debate about whether and how to permit the technique.

The international regulatory patchwork creates the risk of regulatory tourism — families travelling to jurisdictions where the mitochondrial donation technique is available or less strictly regulated, potentially outside robust safety monitoring frameworks. This is one reason why advocates of the technique argue that clear, science-based regulation is preferable to prohibition, which drives practice underground or across borders rather than eliminating it.

Frequently Asked Questions

What is mitochondrial donation treatment?

Mitochondrial donation treatment is an IVF technique that produces an embryo containing nuclear DNA from both biological parents combined with mitochondrial DNA from a healthy donor. It is used to prevent the transmission of serious mitochondrial diseases from mother to child. The child inherits almost all of their genetic identity from their two parents, with the donor contributing only the 37 mitochondrial genes involved in energy production.

What are mitochondrial diseases?

Mitochondrial diseases are conditions caused by mutations in mitochondrial DNA that impair the ability of mitochondria to produce energy. They affect approximately one in 5,000 people and can cause progressive damage to the brain, heart, muscles, and other organs with high energy demands. Severe forms including Leigh syndrome are typically fatal in early childhood. There is currently no cure.

Does a child born using mitochondrial donation have three parents?

In a technical sense, a child born using mitochondrial donation has genetic material from three people. In any meaningful biological or social sense, the child has two parents. The donor contributes only 37 mitochondrial genes — less than 0.1% of the child’s total genetic material — all involved in energy production, with no known influence on physical appearance, personality, or any other heritable trait.

Is mitochondrial donation legal?

Mitochondrial donation treatment is legally available in the United Kingdom through a regulated licencing system. Australia has also licenced the treatment for clinical trials. It remains prohibited in the United States and is in various stages of regulatory consideration in other countries.

Is the technique safe?

Initial safety data from children born using the technique is reassuring, with no serious adverse outcomes reported. However, the oldest children born using the technique are still young, and long-term multigenerational safety data does not yet exist. The risk of mitochondrial reversal — residual mutant mitochondria outcompeting donor mitochondria — is considered low but is being monitored carefully.

Can mitochondrial donation prevent all mitochondrial diseases?

Mitochondrial donation treatment can prevent diseases caused by mutations in mitochondrial DNA. It cannot prevent mitochondrial diseases caused by mutations in nuclear genes — a significant subset of mitochondrial conditions — because nuclear DNA is not replaced in the procedure.

Sources

About the Author

Baryon is the founder and editor of Web News For Us. Driven by a deep fascination with the biggest unanswered questions in science — from quantum physics and cosmology to the nature of consciousness and the genetic code written into every living cell — he has spent years studying modern physics, biology, and the history of scientific thought. He covers Science & AI, Space, Genetics & Research, and the timeless wisdom of history’s greatest thinkers and mystics.

If you have ever looked at the night sky and felt that pull to understand what is out there or wondered about an entire universe coiled inside your genes, you are in the right place.

Share on Facebook

Post on X

Save

Discover more from Web News For Us

Subscribe to get the latest posts sent to your email.